Some recent developed FXR agonist pharmacological agents have beenreported to have promising results in reducing liver damage in treatingnon-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC)diseases4,5. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.